03 Oct 2026, 15:02 IST
Alkem Laboratories Limited
Motilal Oswal (MOFSL) · Neutral
The report forecasts Alkem sales growth of 9.5% YoY and EBITDA growth of 8.4% YoY with PAT declining 13.0% YoY in 2QFY27.
From HEALTHCARE MOFSL PR PG024, written by Motilal Oswal (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.